Paediatric Off-Label Use of Melatonin - A Register Linkage Study between the Norwegian Prescription Database and Patient Register

Basic and Clinical Pharmacology and Toxicology

Volumn 117, Issue 4, 2015, Pages 267-273

  Hartz, Ingeborg ^a   Handal, Marte ^b   Tverdal, Aage ^b   Skurtveit, Svetlana ^b,c  

^a INLAND NORWAY UNIVERSITY OF APPLIED SCIENCES   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; HYPNOTIC SEDATIVE AGENT;

ADOLESCENT; ARTICLE; CHILD; CHILD CARE; FEMALE; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORBIDITY; NEUROLOGIC DISEASE; NORWAY; OFF LABEL DRUG USE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; AGE; CLINICAL PRACTICE; DRUG USE; FACTUAL DATABASE; MEDICAL RECORD; PEDIATRICS; PRESCHOOL CHILD; TIME FACTOR; TRENDS;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MEDICAL RECORD LINKAGE; MELATONIN; NORWAY; OFF-LABEL USE; PEDIATRICS; PRACTICE PATTERNS, PHYSICIANS'; REGISTRIES; TIME FACTORS;

EID: 84940900079     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12411     Document Type: Article

References (45)

1. Hysing M, Pallesen S, Stormark KM, Lundervold AJ, Sivertsen B. Sleep patterns and insomnia among adolescents: a population-based study. J Sleep Res 2013;22:549-56.
2. Bruni O, Novelli L. Sleep disorders in children. Clinical Evidence. 2010;09:2304.
3. Hansen EH, Holstein BE, Due P. Time trends in medicine use among adolescents in ten industrialised countries. Eur J Public Health 2003;13:43.
4. Holstein BE, Holme Hansen E, Due P, Birna Almarsdottir A. Self-reported medicine use among 11- to 15-year-old girls and boys in Denmark 1988-1998. Scand J Public Health 2003;31:334-41.
5. Hartz I, Furu K, Bratlid T, Handal M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004-2011: a nationwide prescription database study. Scand J Public Health 2012;40:704-11.
6. Holstein B, Andersen A, Due P, Hansen EH. Children's and adolescent's use of medicine for aches and psychological problems: secular trends from 1988 to 2006. Ugeskr Laeger 2009;171:24-38.
7. Hsia Y, Maclennan K. Rise in psychotropic drug prescribing in children and adolescents during 1992-2001: a population-based study in the UK. Eur J Epidemiol 2009;24:211-6.
8. Steffenak AKM, Nordstrøm G, Wilde-Larsson B, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: a nationwide prescription database study. Clin Epidemiol 2012;4:225-31.
9. Zoëga H, Baldursson G, Hrafnkelsson B, Almarsdóttir AB, Valdimarsdóttir U, Halldórsson M. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 2009;19:757-64.
10. European Medicines Agency. Summary of product characteristics (SPC) for Circadin (melatonin). Available at: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000695/human_med_000701.jsp&mid=WC0b01ac058001d124 (last accessed on 10 September 2014).
11. British National Formulary for Children. London, BMA/RPSGB, November 2013.
12. The Norwegian Prescription Database, National Institute of Public Health. Available at: www.fhi.no/eway/default.aspx?pid=233&trg=MainArea_5661&MainArea_5661=5565:0:15, 3791:1:0:0:::0:0&MainLeft_5565=5544:50553::1:5569:10:::0:0 (last accessed on 10 December 2014).
13. The Norwegian Patient Register. Available at: http://helsedirektoratet.no/kvalitet-planlegging/norsk-pasientregister-npr/Sider/default.aspx (last accessed on 10 December 2014).
14. WHO Collaborating Centre for Drug Statistics Methodology. ATC Classification Index with DDDs. WHO Collaborating Centre for Drug Statistics Methodology, Oslo.
15. Bakken IJ, Nyland K, Halsteinli V, Kvam U, Skjeldestad F. Norsk pasientregister: administrativ database med mange forskningsmuligheter. Nor Epidemiol 2004;14:65-9.
16. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin-a pleiotropic, orchestrating regulator molecule. Prog Neurobiol 2012;93:350-84.
17. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16:372-80.
18. Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23:2597-605.
19. European Medicines Agency (EMEA). Assessment report for Circadin, 2007. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000695/WC500026808.pdf (last accessed on 10 March 2015).
20. European Medicines Agency (EMEA). Summary of products characteristics: Circadin (melatonin). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000695/WC500026811.pdf (last accessed on 10 March 2015).
21. Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: melatonin for the Treatment of Primary Sleep Disorders. PLoS One 2013;8:e63773.
22. European Medicines Agency (EMEA). Circadin (melatonin)- CHMP assessment report for paediatric use studies submitted according to Article 46 of the Regulation (EC) No 1901/2006 (EMA/85025/2015, 18 December 2014). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000695/WC500182464.pdf (last accessed on 10 March 2015).
23. Cummings C. Melatonin for the management of sleep disorders in children and adolescents. Paediatr Child Health 2012;17:331-3.
24. Bruni O, Alonso-Alconada D, Besag F, Biran V, Braam W, Cortese S et al. Current role of melatonin in pediatric neurology: clinical recommendations. Eur J Paediatr Neurol 2015;19:122-33.
25. Geijlswijk I, Heijden K, Egberts ACG, Korzilius HLM, Smits M. Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia: an RCT. Psychopharmacology (Berl) 2010;212:379-91.
26. Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. J Child Neurol 2001;16:86-92.
27. Smits MG, van Stel H, Van Der Heijden K, Meijer A, Coenen AM, Kerkhof GA. Melatonin improves health status and sleep in children with idiopathic chronic sleep-onset insomnia: a randomized placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2003;42:1286-93.
28. Van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry 2007;46:233-41.
29. Weiss MD, Wasdell MB, Bomben MM, Rea KJ, Freeman RD. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry 2006;45:512-9.
30. National Institute for Health and Care Excellence (NICE). Evidence summary, ESUOM2: Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin. Published 4th January 2013. Available at: https://publications.nice.org.uk/esuom2-sleep-disorders-in-children-and-young-people-with-attention-deficit-hyperactivity-disorder-esuom2/key-points-from-the-evidence (last accessed on 13 March 2015).
31. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev 2006;32:585-9.
32. Wright B, Sims D, Smart S, Alwaseer A, Alderson-Day B, Allgar V et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord 2011;41:175-84.
33. Elkhayat HA, Hassanein SM, Tomoum HY, Abd-Elhamid IA, Asaad T, Elwakkad AS. Melatonin and sleep-related problems in children with intractable epilepsy. Pediatr Neurol 2010;42:249-54.
34. Braam W, Didden R, Smits M, Curfs L. Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo-controlled study. J Intellect Disabil Res 2008;52:256-64.
35. Wasdell MB, Jan JE, Bomben MM et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res 2008;44:57-64.
36. Hardeland R. Melatonin in aging and disease - multiple consequences of reduced secretion, options and limits of treatment. Aging Dis 2012;3:194-225.
37. Reiter RJ, Rosales-Corral SA, Manchester LC, Tan D-X. Peripheral reproductive organ health and melatonin: ready for prime time. Int J Mol Sci 2013;14:7231-72.
38. Srinivasan V, Spence DW, Pandi-Perumal SR, Zakhira R, Bhatnager KP, Brzezinski A. Melatonin and human reproduction: shedding light on the darkness hormone. Gynecol Endocrinol 2009;25:779-85.
39. Shi L, Li N, Bo L, Xu Z. Melatonin and hypothalamic-pituitary-gonadal axis. Curr Med Chem 2013;20:2017-31.
40. Lampiao F, Du Plessis SS. New developments of the effect of melatonin on reproduction. World J Obstet Gynecol 2013;2:15-22.
41. Tamura H, Takasaki A, Taketani T et al. Melatonin and female reproduction. J Obstet Gynaecol Res 2013;40:1-14.
42. Geijlswijk I, Mol R, Egberts TG, Smits M. Evaluation of sleep, puberty and mental health in children with long-term melatonin treatment for chronic idiopathic childhood sleep onset insomnia. Psychopharmacology 2011;216:111-20.
43. The National Board of Health and Welfare in Sweden, prescription statistics. Available at: http://www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel (last accessed on 21 October 2014).
44. National Institute for Health Data and Disease Control, statistics on the total sales of medicines in Denmark 1996-2012. Available at: http://medstat.dk/ (last accessed on 21 October 2013).
45. Danish Medicines and Health Authoratives (Sundhetsstyrelsen). Users of melatonin <25 years of age (in Danish: Brugere under 25 år af lægemidler med melatonin (2013). Report available at: http://sundhedsstyrelsen.dk/da/udgivelser/2013/~/media/7F854F552D5642C59A5C479804D4E451.ashx (last accessed on 6 March 2015).